(NASDAQ: INZY) Inozyme Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Inozyme Pharma's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast INZY's revenue for 2026 to be $1,197,758,492, with the lowest INZY revenue forecast at $1,927,206, and the highest INZY revenue forecast at $2,393,589,777. On average, 5 Wall Street analysts forecast INZY's revenue for 2027 to be $4,884,888,896, with the lowest INZY revenue forecast at $1,229,557,390, and the highest INZY revenue forecast at $7,995,977,445.
In 2028, INZY is forecast to generate $16,819,561,361 in revenue, with the lowest revenue forecast at $8,737,951,732 and the highest revenue forecast at $26,285,804,218.